RNAi News GenomeWeb News Premium Content Existing subscribers login here. New to RNAi News? For a trial subscription click here.

Quark Taps Glaucoma Drug to Be Its First
Novel RNAi Agent, CEO Speaks Out on Silence

[July 17, 2008]

By Doug Macron

Quark’s investigational glaucoma treatment would be its first completely proprietary siRNA drug, which is expected to help the company avoid the kind of confusion it said has plagued its other clinical candidates, which incorporate chemical structures licensed from other firms.

Login | Subscribe